Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer (EndoTAG-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01537536
Recruitment Status : Completed
First Posted : February 23, 2012
Last Update Posted : June 17, 2013
Information provided by (Responsible Party):
Jules Bordet Institute